Your Health, We Care
On October 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved Revuforj (generic name: revumenib) for the treatment of adult and pediatric patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 gene mutation.
On November 15, 2024, the U.S. Food and Drug Administration (FDA) approved Revuforj (generic name: revumenib) for the treatment of adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A gene translocation.
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) ···【more】
Recommended：132026-28-01
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from B-lineage or T-linea···【more】
Recommended：142026-28-01
Recently, Syndax Pharmaceuticals announced additional positive data from the AUGMENT-101 trial of Re···【more】
Recommended：142026-28-01
On June 24, 2025, Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the supplemental New Drug Application (sNDA) for ···【more】
Article source：Lucius LaosRelease date：2026-01-28Recommended：13
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy originating from B-lineage or T-lineage lymphoid cells. Most adult ALL cases have an acute onset, with fever, bleedin···【more】
Article source：Lucius LaosRelease date：2026-01-28Recommended：14
Recently, Syndax Pharmaceuticals announced additional positive data from the AUGMENT-101 trial of Revuforj (revumenib) in patients with relapsed or refractory (R/R) nucleophosmin 1···【more】
Article source：Lucius LaosRelease date：2026-01-28Recommended：14
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
